Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Efstathiou

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2015
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3Ahmad Salameh, Alessandro K Lee, Marina Cardó-Vila, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2011
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patientsFernanda I Staquicini, Marina Cardó-Vila, Mikhail G Kolonin, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international databaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
The Prostate|August 4, 2018
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) modelsNora M Navone, Wytske M van Weerden, Robert L Vessella, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2020
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2020
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
European Urology Oncology|June 4, 2019
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS DatabaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2015
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3Ahmad Salameh, Alessandro K Lee, Marina Cardó-Vila, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2011
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patientsFernanda I Staquicini, Marina Cardó-Vila, Mikhail G Kolonin, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international databaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
The Prostate|August 4, 2018
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) modelsNora M Navone, Wytske M van Weerden, Robert L Vessella, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2020
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2020
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
European Urology Oncology|June 4, 2019
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS DatabaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Pageof 15